Ocrelizumab treatment in multiple sclerosis: A Danish population‐based cohort studyLuigi Pontieri, Melinda Magyari, Hanna Joensen et al.|European Journal of Neurology|2021Cited by 29
Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis RegistryViktoria Papp, Melinda Magyari, Mathias Due Buron et al.|PLoS ONE|2021Cited by 20
The effectiveness of natalizumab vs fingolimod–A comparison of international registry studiesJohanna Balslev Andersen, Gilles Edan, Sifat Sharmin et al.|Multiple Sclerosis and Related Disorders|2021Cited by 12
Rebound of clinical disease activity after fingolimod discontinuation? A nationwide cohort study of patients in DenmarkElisabeth Framke, Melinda Magyari, Luigi Pontieri et al.|Journal of Neurology Neurosurgery & Psychiatry|2022Cited by 9
Application of definitions for conversion to secondary progressive MS in a Danish nationwide populationTine Iskov Kopp, Melinda Magyari, Stephan Bramow et al.|Multiple Sclerosis and Related Disorders|2021Cited by 8